Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 35-41

  Vergis, Roy ^a   Corbishley, Catherine M ^c   Thomas, Karen ^b   Horwich, Alan ^a   Huddart, Robert ^a   Khoo, Vincent ^a   Eeles, Ros ^a   Sydes, Matthew R ^d   Cooper, Colin S ^a   Dearnaley, David ^a   Parker, Chris ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Apoptotic markers; Dose escalation; Prostate; Radiotherapy

Indexed keywords

ANDROGEN DEPRIVATION; APOPTOTIC MARKERS; BIOCHEMICAL CONTROL; BIOPSY TISSUES; DOSE ESCALATION; FREEDOM FROM BIOCHEMICAL FAILURES; GLEASON SCORES; IMMUNOHISTOCHEMISTRY; LOCALIZED PROSTATE CANCER; MULTI VARIATE ANALYSIS; PROGNOSTIC FACTORS; PROSTATE; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADICAL RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; UNIVARIATE ANALYSIS;

BIOPSY; DISEASES; MULTIVARIANT ANALYSIS; TUMORS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RADIOTHERAPY DOSAGE; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955862497     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1728     Document Type: Article

References (43)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
2. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101 (Pubitemid 40617061)
3. J. Cuzick, G. Fisher, and M.W. Kattan Long-term outcome among men with conservatively treated localised prostate cancer Br J Cancer 95 2006 1186 1194
4. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Natl Cancer Inst 98 2006 715 717
5. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
6. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
7. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
8. S. Denmeade, and J. Isaacs Activation of programmed (apoptotic) cell death for the treatment of prostate cancer Adv Pharmacol 35 1996 -306
9. M.J. Szostak, and N. Kyprianou Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review) Oncol Rep 7 2000 699 706
10. T.J. McDonnell, P. Troncoso, and S.M. Brisbay Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944
11. J.J. Bauer, D.G. McLeod, and J.W. Moul Prostate cancer: Diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994 Mil Med 161 1996 646 653
12. M. Krajewska, S. Krajewski, and J.I. Epstein Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers Am J Pathol 148 1996 1567 1576
13. R. Autorino, G. Di Lorenzo, and R. Damiano Role of chemotherapy in hormone-refractory prostate cancer: Old issues, recent advances and new perspectives Urol Int 70 2003 1 14
14. D.R. Shaffer, and H.I. Scher Prostate cancer: A dynamic illness with shifting targets Lancet Oncol 4 2003 407 414
15. C.J. Rosser, A.O. Reyes, and F. Vakar-Lopez Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma Int J Radiat Oncol Biol Phys 56 2003 1 6
16. M. Krajewska, S.F. Moss, and S. Krajewski Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas Cancer Res 56 1996 2422 2427
17. F.L. Hering, M.V. Lipay, and M.A. Lipay Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score Sao Paulo Med J 119 2001 138 141
18. M. Colombel, F. Symmans, and S. Gil Detection of the apoptosis- suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers Am J Pathol 143 1993 390 400
19. Z. Mu, P. Hachem, and A. Pollack Antisense Bcl-2 sensitizes prostate cancer cells to radiation Prostate 65 2005 331 340
20. J. An, A.S. Chervin, A. Nie, and H.S. Ducoff Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor Oncogene 26 2007 652 661
21. A. Pollack, D. Cowen, and P. Troncoso Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x Cancer 97 2003 1630 1638
22. T.J. Mackey, A. Borkowski, and P. Amin bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer Urology 52 1998 1085 1090
23. J.J. Bauer, I.A. Sesterhenn, and F.K. Mostofi Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer J Urol 156 1996 1511 1516
24. M.J. Szostak, P. Kaur, P. Amin, and S.C. Jacobs Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy J Urol 165 Pt 1 2001 2126 2130
25. D.S. Scherr, E.D. Vaughan Jr., and J. Wei BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy J Urol 162 1999 12 16 discussion 16-17
26. L.Y. Khor, J. Moughan, and T. Al-Saleem Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02 Clin Cancer Res 13 2007 3585 3590
27. L.Y. Khor, M. Desilvio, and R. Li Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10 Int J Radiat Oncol Biol Phys 66 2006 25 30
28. A. Bylund, P. Stattin, and A. Widmark Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy Radiother Oncol 49 1998 143 148
29. B. Vogelstein, and K.W. Kinzler p53 function and dysfunction Cell 70 1992 523 526
30. D.G. Kirsch, and M.B. Kastan Tumor-suppressor p53: implications for tumor development and prognosis J Clin Oncol 16 1998 3158 3168
31. M.A. Ritter, K.W. Gilchrist, and M. Voytovich The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer Int J Radiat Oncol Biol Phys 53 2002 574 580
32. D.J. Grignon, R. Caplan, and F.H. Sarkar p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610 J Natl Cancer Inst 89 1997 158 165
33. M. Che, M. DeSilvio, and A. Pollack Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: A study based on RTOG 9202 Int J Radiat Oncol Biol Phys 69 2007 1117 1123
34. J. Momand, G.P. Zambetti, and D.C. Olson The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
35. K.R. Leite, M.F. Franco, and M. Srougi Abnormal expression of MDM2 in prostate carcinoma Mod Pathol 14 2001 428 436
36. D.B. Agus, C. Cordon-Cardo, and W. Fox Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence J Natl Cancer Inst 91 1999 1869 1876
37. L.Y. Khor, M. Desilvio, and T. Al-Saleem MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group Protocol 8610 Cancer 104 2005 962 967
38. M.R. Sydes, R.J. Stephens, and A.R. Moore Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): Methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer Radiother Oncol 72 2004 199 211
39. D.P. Dearnaley, E. Hall, and D. Lawrence Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects Br J Cancer 92 2005 488 498
40. S. Jhavar, C.M. Corbishley, and D. Dearnaley Construction of tissue microarrays from prostate needle biopsy specimens Br J Cancer 93 2005 478 482
41. R. Stoyanova, P. Hachem, and H. Hensley Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo Int J Radiat Oncol Biol Phys 68 2007 1151 1160
42. S. Anai, S. Goodison, and K. Shiverick Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts Mol Cancer Ther 6 2007 101 111
43. R. Vergis, C.M. Corbishley, and A.R. Norman Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study Lancet Oncol 9 2008 342 351